Campbell & CO Investment Adviser LLC Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL

Campbell & CO Investment Adviser LLC cut its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 50.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,207 shares of the specialty pharmaceutical company’s stock after selling 19,545 shares during the period. Campbell & CO Investment Adviser LLC owned 0.06% of Collegium Pharmaceutical worth $672,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. CWM LLC grew its holdings in shares of Collegium Pharmaceutical by 453.9% in the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 1,153 shares during the period. EverSource Wealth Advisors LLC grew its stake in Collegium Pharmaceutical by 744.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after purchasing an additional 2,190 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Collegium Pharmaceutical by 368.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock worth $82,000 after acquiring an additional 2,169 shares in the last quarter. NewEdge Advisors LLC raised its holdings in Collegium Pharmaceutical by 304.6% during the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 2,294 shares in the last quarter. Finally, EMC Capital Management purchased a new stake in shares of Collegium Pharmaceutical during the 2nd quarter worth approximately $97,000.

Insider Activity at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the transaction, the chief financial officer owned 126,667 shares of the company’s stock, valued at approximately $5,133,813.51. This trade represents a 19.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the transaction, the director directly owned 52,629 shares in the company, valued at approximately $2,475,141.87. This represents a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 51,250 shares of company stock valued at $2,235,352 over the last 90 days. 2.51% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $47.70 on Wednesday. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of 29.63 and a beta of 0.60. The company has a debt-to-equity ratio of 2.71, a current ratio of 1.36 and a quick ratio of 1.27. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $50.79. The business has a 50-day moving average of $47.20 and a 200-day moving average of $39.43.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.89 by $0.36. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The business had revenue of $209.36 million during the quarter, compared to analyst estimates of $191.25 million. During the same quarter in the previous year, the firm earned $1.61 earnings per share. The business’s revenue was down 18.9% compared to the same quarter last year. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the company. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Barclays reduced their target price on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a report on Friday, January 9th. Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. HC Wainwright restated a “buy” rating and issued a $60.00 price target (up previously from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Finally, Needham & Company LLC boosted their price objective on shares of Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $52.80.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.